BG108537A - Единична доза азитромицин - Google Patents

Единична доза азитромицин Download PDF

Info

Publication number
BG108537A
BG108537A BG108537A BG10853704A BG108537A BG 108537 A BG108537 A BG 108537A BG 108537 A BG108537 A BG 108537A BG 10853704 A BG10853704 A BG 10853704A BG 108537 A BG108537 A BG 108537A
Authority
BG
Bulgaria
Prior art keywords
dose
azithromycin
use according
treatment
single dose
Prior art date
Application number
BG108537A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Dunne
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG108537A publication Critical patent/BG108537A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG108537A 2001-08-21 2004-01-21 Единична доза азитромицин BG108537A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31386701P 2001-08-21 2001-08-21

Publications (1)

Publication Number Publication Date
BG108537A true BG108537A (bg) 2005-02-28

Family

ID=23217490

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108537A BG108537A (bg) 2001-08-21 2004-01-21 Единична доза азитромицин

Country Status (25)

Country Link
US (3) US20030148964A1 (fr)
EP (1) EP1418924A2 (fr)
JP (1) JP2005501862A (fr)
KR (1) KR20040032942A (fr)
AP (1) AP1729A (fr)
BG (1) BG108537A (fr)
BR (1) BR0211830A (fr)
CA (1) CA2458135A1 (fr)
CZ (1) CZ2004232A3 (fr)
EA (1) EA200400214A1 (fr)
EC (1) ECSP044985A (fr)
GE (1) GEP20063812B (fr)
HR (1) HRP20040163A2 (fr)
HU (1) HUP0401332A2 (fr)
IL (1) IL159585A0 (fr)
IS (1) IS7092A (fr)
MA (1) MA27059A1 (fr)
MX (1) MXPA04001605A (fr)
OA (1) OA12845A (fr)
PL (1) PL367888A1 (fr)
SK (1) SK1012004A3 (fr)
TN (1) TNSN04035A1 (fr)
WO (1) WO2003018031A2 (fr)
YU (1) YU8804A (fr)
ZA (1) ZA200400804B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648473B1 (fr) * 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Dose unique a dissolution rapide d'azithromycine
ATE399536T1 (de) 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CA2547597A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions multiparticulaires a stabilite amelioree
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) * 2007-06-26 2009-01-01 Idexx Laboratories, Inc. Single dose roxithromycin
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
US20110105421A1 (en) * 2008-03-14 2011-05-05 The Florida International University Board Of Trustees Ellagitannins as inhibitors of bacterial quorum sensing
EP2717909B1 (fr) 2011-06-04 2017-12-06 Rochester General Hospital Research Institute Compositions et procédés associés à la protéine p6 de l'haemophilus influenzae
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
CA2949078C (fr) * 2014-05-15 2022-09-20 Insmed Incorporated Methodes de traitement d'infections pulmonaires mycobacteriennes non-tuberculeuses
EP3773505A4 (fr) 2018-03-30 2021-12-22 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
WO2021163451A1 (fr) * 2020-02-14 2021-08-19 Asklepios Biopharmaceutical, Inc. Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53264A (en) * 1866-03-20 Improved ditching-machine
SI7910768A8 (en) 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
UA27040C2 (uk) 1987-07-09 2000-02-28 Пфайзер Інк. Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу
WO1989002271A1 (fr) 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
YU45590A (sh) 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (fr) 1992-07-30 1996-03-01 Pfizer
DK0699207T3 (da) 1993-05-19 1997-12-08 Pfizer Mellemprodukt til azithromycin
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CN1096862C (zh) 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US20040053264A1 (en) * 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips

Also Published As

Publication number Publication date
GEP20063812B (en) 2006-05-10
IS7092A (is) 2003-12-23
HRP20040163A2 (en) 2005-02-28
MA27059A1 (fr) 2004-12-20
EA200400214A1 (ru) 2004-06-24
EP1418924A2 (fr) 2004-05-19
ECSP044985A (es) 2004-04-28
US20040023898A1 (en) 2004-02-05
IL159585A0 (en) 2004-06-01
US6987093B2 (en) 2006-01-17
CA2458135A1 (fr) 2003-03-06
AP2004002968A0 (en) 2004-03-31
OA12845A (en) 2006-09-15
US20050250712A1 (en) 2005-11-10
US20030148964A1 (en) 2003-08-07
JP2005501862A (ja) 2005-01-20
WO2003018031A3 (fr) 2003-10-02
SK1012004A3 (sk) 2005-04-01
MXPA04001605A (es) 2004-07-08
HUP0401332A2 (hu) 2004-11-29
YU8804A (sh) 2006-08-17
TNSN04035A1 (fr) 2006-06-01
ZA200400804B (en) 2005-05-03
PL367888A1 (en) 2005-03-07
BR0211830A (pt) 2004-09-08
WO2003018031A2 (fr) 2003-03-06
CZ2004232A3 (cs) 2005-10-12
AP1729A (en) 2007-03-26
US7067493B2 (en) 2006-06-27
KR20040032942A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
McCracken The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis
BG108537A (bg) Единична доза азитромицин
Norden et al. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus
Amin Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats
Marchi Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis
MOOSA et al. Once daily ceftriaxone vs. chloramphenicol for treatment of typhoid fever in children
Marshak et al. Recurrent pneumococcal otitis media in the chinchilla: a longitudinal study
Smilack et al. Mycoplasma pneumoniae pneumonia and clindamycin therapy: failure to demonstrate efficacy
Vidal et al. Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite Deoxycholic acid
McLinn Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review
Lari et al. Comparison of cefuroxime and co-amoxiclav in the treatment of acute sinusitis in a sample of the Iranian population
CN114375200A (zh) 治疗传染病的药物和方法
AU2020203634B2 (en) Treating or preventing respiratory infection
AU2002313574A1 (en) Single dose azithromycin for treating respiratory infections
CN103458681A (zh) 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
Ruiz-Bedoya et al. 191. High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis
Bergelson et al. Pediatric Infectious Diseases E-Book: Requisites
Mattos Filho et al. Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin: in vivo study in rats
Flume A role for aerosolized antibiotics
Dandekar et al. Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model
Gill et al. 1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and Pseudomonas aeruginosa (PA) in the Neutropenic Murine Thigh Infection Model
Shimizu et al. The haemodialysis patient who developed acute respiratory distress syndrome after a trip to a hot spring spa.
RU2180532C2 (ru) Способ лечения папилломатоза
JPS59116217A (ja) マイコプラズマ感染症用薬
RU2306149C2 (ru) Способ лечения больных с затяжной пневмонией с применением препарата "рузам"